MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
MannKind (Nasdaq: MNKD), a company specializing in inhaled therapeutic products for endocrine and orphan lung diseases, will participate in the 2024 Cantor Fitzgerald Global Healthcare Conference in New York. Chief Financial Officer Chris Prentiss and Dr. Wasim Fares, Therapeutic Area Head for Orphan Lung Diseases, will present during a fireside chat on Wednesday, September 18 at 1:20 p.m. Eastern Time.
The presentation will be accessible via a live audio webcast on MannKind's website, with a recorded version available for approximately 30 days after the event. This conference provides an opportunity for MannKind to share updates on their innovative therapeutic products and connect with healthcare industry professionals.
MannKind (Nasdaq: MNKD), un'azienda specializzata in prodotti terapeutici inalati per malattie endocrine e polmonari rare, parteciperà alla 2024 Cantor Fitzgerald Global Healthcare Conference a New York. Il Direttore Finanziario Chris Prentiss e Dr. Wasim Fares, Responsabile dell'Area Terapeutica per le Malattie Polmonari Rare, presenteranno durante una conversazione informale mercoledì 18 settembre alle 13:20 ora orientale.
La presentazione sarà accessibile tramite un webcast audio dal vivo sul sito web di MannKind, con una versione registrata disponibile per circa 30 giorni dopo l'evento. Questa conferenza offre un'opportunità per MannKind di condividere aggiornamenti sui loro innovativi prodotti terapeutici e connettersi con professionisti del settore sanitario.
MannKind (Nasdaq: MNKD), una empresa especializada en productos terapéuticos inhalados para enfermedades endócrinas y pulmonares huérfanas, participará en la 2024 Cantor Fitzgerald Global Healthcare Conference en Nueva York. El Director Financiero Chris Prentiss y el Dr. Wasim Fares, Jefe del Área Terapéutica de Enfermedades Pulmonares Huérfanas, presentarán durante una charla informal el miércoles 18 de septiembre a la 1:20 p.m. hora del este.
La presentación será accesible a través de un webcast de audio en vivo en el sitio web de MannKind, con una versión grabada disponible durante aproximadamente 30 días después del evento. Esta conferencia proporciona una oportunidad para que MannKind comparta actualizaciones sobre sus innovadores productos terapéuticos y se conecte con profesionales de la industria de la salud.
맨카인드 (Nasdaq: MNKD), 내분비 및 희귀 폐 질환을 위한 흡입 치료 제품에 전문화된 회사가 뉴욕에서 열리는 2024 칸토르 피츠제럴드 글로벌 헬스케어 컨퍼런스에 참석합니다. 최고 재무 책임자 크리스 프렌티스와 와심 파레스 박사, 희귀 폐 질환 치료 부문 책임자가 9월 18일 수요일 오후 1:20 (동부 표준시)에 진행되는 대화에 참석합니다.
이 발표는 맨카인드 웹사이트에서 실시간 오디오 웹캐스트를 통해 접근 가능하며, 행사 후 약 30일 동안 녹화된 버전이 제공될 예정입니다. 이번 컨퍼런스는 맨카인드가 혁신적인 치료 제품에 대한 업데이트를 공유하고 헬스케어 산업 전문가들과 연결할 수 있는 기회를 제공합니다.
MannKind (Nasdaq: MNKD), une entreprise spécialisée dans les produits thérapeutiques inhalés pour les maladies endocriniennes et pulmonaires rares, participera à la 2024 Cantor Fitzgerald Global Healthcare Conference à New York. Le Directeur Financier Chris Prentiss et Dr. Wasim Fares, Responsable de la Zone Thérapeutique pour les Maladies Pulmonaires Rares, présenteront lors d'une discussion chaleureuse le mercredi 18 septembre à 13h20, heure de l'Est.
La présentation sera accessible via un webcast audio en direct sur le site de MannKind, avec une version enregistrée disponible pendant environ 30 jours après l'événement. Cette conférence offre à MannKind l'opportunité de partager des mises à jour sur leurs produits thérapeutiques innovants et de se connecter avec des professionnels de l'industrie de la santé.
MannKind (Nasdaq: MNKD), ein Unternehmen, das sich auf inhalative Therapeutika für endokrine und seltene Lungenerkrankungen spezialisiert hat, wird an der 2024 Cantor Fitzgerald Global Healthcare Conference in New York teilnehmen. Finanzvorstand Chris Prentiss und Dr. Wasim Fares, Bereichsleiter für seltene Lungenerkrankungen, werden am Mittwoch, den 18. September um 13:20 Uhr Eastern Time in einem informellen Gespräch präsentieren.
Die Präsentation wird über einen Live-Audio-Webcast auf der Website von MannKind zugänglich sein, mit einer aufgezeichneten Version, die etwa 30 Tage nach der Veranstaltung verfügbar sein wird. Diese Konferenz bietet MannKind die Gelegenheit, Neuigkeiten zu ihren innovativen therapeutischen Produkten zu teilen und mit Fachleuten der Gesundheitsbranche in Kontakt zu treten.
- None.
- None.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Financial Officer Chris Prentiss and Dr. Wasim Fares Therapeutic Area Head, Orphan Lung Diseases, will share updates during a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference in New York.
The fireside chat will take place on Wednesday, September 18 beginning at 1:20 p.m. Eastern Time. A link to the live audio webcast of the session will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. An archived, recorded version will also be available on the website for approximately 30 days following the conference.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
MANNKIND is a registered trademark of MannKind Corporation.
FAQ
When is MannKind (MNKD) presenting at the 2024 Cantor Fitzgerald Global Healthcare Conference?
Who will be representing MannKind (MNKD) at the 2024 Cantor Fitzgerald Global Healthcare Conference?
How can I access MannKind's (MNKD) presentation at the 2024 Cantor Fitzgerald Global Healthcare Conference?
What type of products does MannKind (MNKD) focus on developing?
How long will the recorded version of MannKind's (MNKD) presentation be available on their website?
